Valuation : Haleon plc

Market Cap 31.08B 42.02B 36.16B 34.02B 58.14B 3,967B 58.3B 402B 156B 2,036B 158B 154B 6,558B P/E 2026 *
18.4x
P/E 2027 * 16.2x
Enterprise Value 37.95B 51.32B 44.16B 41.55B 71B 4,845B 71.19B 491B 191B 2,486B 193B 188B 8,008B EV / Sales 2026 *
3.33x
EV / Sales 2027 * 3.15x
Free-Float
98.46%
Yield 2026 *
2.29%
Yield 2027 * 2.53%

Last Transcript : Haleon plc

1 day-2.64%
1 week-5.04%
Current month-4.29%
1 month-4.29%
3 months+5.26%
6 months-6.61%
Current year-5.04%
1 week 9.57
Extreme 9.57
10.2
1 month 9.56
Extreme 9.565
10.26
Current year 8.65
Extreme 8.65
11.28
1 year 8.65
Extreme 8.65
11.28
3 years 7.7
Extreme 7.695
11.42
5 years 5.59
Extreme 5.59
11.42
10 years 5.59
Extreme 5.59
11.42
Manager TitleAgeSince
Chief Executive Officer 59 2021-07-21
Director of Finance/CFO 58 2024-10-31
Chief Tech/Sci/R&D Officer 63 2025-07-31
Director TitleAgeSince
Director/Board Member 59 2022-05-22
Chairman 71 2025-12-31
Director/Board Member 59 2022-07-17
Change 5-day change 1-year change 3-year change Capi.($)
-2.64%-5.04% - - 42.02B
-0.88%-2.15%+58.05%+105.26% 1,024B
-1.15%+2.68%+54.25%+74.19% 663B
-1.44%+0.38%+20.65%+76.13% 453B
+0.14%-0.47%+30.20%+41.44% 352B
-1.33%+4.72%+24.62%+48.58% 304B
-1.15%+0.30%-0.69%+13.20% 252B
-1.55%+1.11%+54.15%+75.59% 236B
-0.88%+1.15%-14.60%-54.96% 206B
-0.15%+3.65%+31.24%+103.39% 187B
Average -1.10%+1.26%+28.65%+53.65% 408.71B
Weighted average by Cap. -0.98%+0.62%+37.63%+68.01%

Financials

2026 *2027 *
Net sales 11.39B 15.4B 13.25B 12.47B 21.31B 1,454B 21.36B 147B 57.17B 746B 57.82B 56.56B 2,403B 11.86B 16.04B 13.8B 12.99B 22.2B 1,515B 22.26B 153B 59.56B 777B 60.24B 58.93B 2,504B
Net income 1.69B 2.29B 1.97B 1.86B 3.17B 216B 3.18B 21.92B 8.51B 111B 8.6B 8.42B 358B 1.92B 2.59B 2.23B 2.1B 3.58B 245B 3.59B 24.79B 9.62B 126B 9.73B 9.52B 404B
Net Debt 6.88B 9.3B 8B 7.53B 12.86B 878B 12.9B 88.94B 34.51B 450B 34.91B 34.15B 1,451B 6.27B 8.47B 7.29B 6.86B 11.72B 800B 11.75B 81.06B 31.46B 410B 31.82B 31.12B 1,322B
Logo Haleon plc
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (31.4%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - pain relief medicines (23.2%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - respiratory medicines (17%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (15.3%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc.; - medicines for digestive health (8.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - other (4.2%). Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (41.6%), North America (35.1%), and Asia/Pacific (23.3%).
Employees
24,535
Date Price Change Volume
26-09-04 US$9.600 -2.64% 18,166,343
26-09-03 US$9.860 -0.50% 16,796,629
26-09-02 US$9.910 -1.59% 10,528,402
26-09-01 US$10.07 +0.40% 11,244,021
26-08-31 US$10.03 -0.79% 8,404,575
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.528GBP
Average target price
4.211GBP
Spread / Average Target
+19.36%

Quarterly revenue - Rate of surprise